NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-.

Cover of LiverTox

LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet].

Show details

Phenyltoloxamine

Last Update: January 16, 2017.

OVERVIEW

Introduction

Phenyltoloxamine is a first generation antihistamine that is used for symptoms of the common cold and as a short acting sedative. Phenyltoloxamine has not been linked to instances of clinically apparent acute liver injury.

Background

Phenyltoloxamine (fen" il tol ox' a meen) is a first generation antihistamine that is used to treat the symptoms of the common cold, including sneezing, cough, runny note, watery eyes and itching. Because of its sedating side effects, it is also used as a mild sleeping aid and sedative. Phenyltoloxamine belongs to the ethanolamine class of antihistamines (with clemastine and dimenhydrinate) and is currently used largely in combination with other agents such as phenylephrine and acetaminophen in over-the-counter products for relief of symptoms of the common cold and nighttime relief of minor aches and pains. Representative brand names of products that include phenyltoloxamine include Dologesic and Relagesic. The typical adult oral dose is 30 to 50 mg. Common side effects include sedation, impairment of motor function, confusion, dizziness, blurred vision, dry mouth and throat, palpitations, tachycardia, abdominal distress, constipation and headache. Antihistamines can worsen urinary retention and glaucoma.

Hepatotoxicity

Like most first generation antihistamines, phenyltoloxamine has not been linked to liver test abnormalities or to clinically apparent liver injury. The reason for its safety may relate its short half-life and limited duration of use.

References on the safety and potential hepatotoxicity of antihistamines are given together after the Overview section on Antihistamines.

Likelihood score: E (unlikely to be a cause of clinically apparent liver injury).

Drug Class: Antihistamines

PRODUCT INFORMATION

REPRESENTATIVE TRADE NAMES

Phenyltoloxamine – Dologesic®, Relagesic®

DRUG CLASS

Antihistamines

COMPLETE LABELING

Product labeling at DailyMed, National Library of Medicine, NIH

CHEMICAL FORMULA AND STRUCTURE

DRUGCAS REGISTRY NUMBERMOLECULAR FORMULASTRUCTURE
Phenyltoloxamine92-12-6C17-H21-N-O
Phenyltoloxamine Chemical Structure

Views

Similar articles in PubMed

  • Review Doxylamine[LiverTox: Clinical and Researc...]
    Review Doxylamine
    . LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. 2012
  • Review Triprolidine[LiverTox: Clinical and Researc...]
    Review Triprolidine
    . LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. 2012
  • Review Clemastine[LiverTox: Clinical and Researc...]
    Review Clemastine
    . LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. 2012
  • Review Carbinoxamine[LiverTox: Clinical and Researc...]
    Review Carbinoxamine
    . LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. 2012
  • Review Diphenhydramine[LiverTox: Clinical and Researc...]
    Review Diphenhydramine
    . LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. 2012
See reviews...See all...

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...